COHEN CHARLES J. 4
4 · Xenon Pharmaceuticals Inc. · Filed Feb 14, 2018
Insider Transaction Report
Form 4
COHEN CHARLES J.
VP, Biology
Transactions
- Exercise/Conversion
Common Shares
2018-02-12$3.71/sh+26,748$99,235→ 26,748 total - Tax Payment
Common Shares
2018-02-12$3.50/sh−22,669$79,342→ 4,079 total - Exercise/Conversion
Stock Option (Right to Buy)
2018-02-12−26,748→ 0 totalExercise: $3.71Exp: 2018-03-16→ Common Shares (26,748 underlying)
Footnotes (3)
- [F1]The exercise price was converted to U.S. dollars from $3.74 CAD using the closing rate of exchange on the Bank of Canada on the date of grant. The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the day of exercise.
- [F2]Represents the closing price of the Company's common shares on February 09, 2018, which was converted to $4.41 Canadian for purposes of net settlement calculations.
- [F3]The shares subject to the option fully vested on January 31, 2012. The date the option became fully vested was incorrectly reflected on the Reporting Person's Form 3.